TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has shared an announcement.
Hangzhou Tigermed Consulting Co., Ltd. has announced the convening of its 2025 first extraordinary general meeting to discuss and approve several key resolutions. These include amendments to the company’s Articles of Association, Rules of Procedure for General Meetings and Board of Directors’ Meetings, and a proposal to reduce registered capital. The meeting will also address amendments to various management rules and grant authority to negotiate audit fees, reflecting the company’s ongoing efforts to refine its governance and operational frameworks.
The most recent analyst rating on (HK:3347) stock is a Hold with a HK$54.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a leading clinical research service provider in China, offering a comprehensive range of services for the pharmaceutical and biotechnology industries. The company focuses on delivering high-quality clinical trial solutions to support drug development and regulatory approval processes.
YTD Price Performance: 69.05%
Average Trading Volume: 4,536,555
Technical Sentiment Signal: Buy
Current Market Cap: HK$56.14B
For a thorough assessment of 3347 stock, go to TipRanks’ Stock Analysis page.